Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements

This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emerge...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yongchang, Huang, Zhe, Zeng, Liang, Zhang, Xiangyu, Li, Yizhi, Xu, Qinqin, Yang, Haiyan, Lizaso, Analyn, Xu, Chunwei, Liu, Jun, Wang, Wenxian, Song, Zhengbo, Ou, Sai-Hong Ignatius, Yang, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971474/
https://www.ncbi.nlm.nih.gov/pubmed/35361870
http://dx.doi.org/10.1038/s41698-022-00264-w
_version_ 1784679640754814976
author Zhang, Yongchang
Huang, Zhe
Zeng, Liang
Zhang, Xiangyu
Li, Yizhi
Xu, Qinqin
Yang, Haiyan
Lizaso, Analyn
Xu, Chunwei
Liu, Jun
Wang, Wenxian
Song, Zhengbo
Ou, Sai-Hong Ignatius
Yang, Nong
author_facet Zhang, Yongchang
Huang, Zhe
Zeng, Liang
Zhang, Xiangyu
Li, Yizhi
Xu, Qinqin
Yang, Haiyan
Lizaso, Analyn
Xu, Chunwei
Liu, Jun
Wang, Wenxian
Song, Zhengbo
Ou, Sai-Hong Ignatius
Yang, Nong
author_sort Zhang, Yongchang
collection PubMed
description This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly for patients who developed extracranial-only disease progression. Our findings highlight the importance of rebiopsy and gene testing for subsequent-line therapeutic management.
format Online
Article
Text
id pubmed-8971474
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89714742022-04-20 Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements Zhang, Yongchang Huang, Zhe Zeng, Liang Zhang, Xiangyu Li, Yizhi Xu, Qinqin Yang, Haiyan Lizaso, Analyn Xu, Chunwei Liu, Jun Wang, Wenxian Song, Zhengbo Ou, Sai-Hong Ignatius Yang, Nong NPJ Precis Oncol Brief Communication This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly for patients who developed extracranial-only disease progression. Our findings highlight the importance of rebiopsy and gene testing for subsequent-line therapeutic management. Nature Publishing Group UK 2022-03-31 /pmc/articles/PMC8971474/ /pubmed/35361870 http://dx.doi.org/10.1038/s41698-022-00264-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Zhang, Yongchang
Huang, Zhe
Zeng, Liang
Zhang, Xiangyu
Li, Yizhi
Xu, Qinqin
Yang, Haiyan
Lizaso, Analyn
Xu, Chunwei
Liu, Jun
Wang, Wenxian
Song, Zhengbo
Ou, Sai-Hong Ignatius
Yang, Nong
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
title Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
title_full Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
title_fullStr Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
title_full_unstemmed Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
title_short Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
title_sort disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ros1 rearrangements
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971474/
https://www.ncbi.nlm.nih.gov/pubmed/35361870
http://dx.doi.org/10.1038/s41698-022-00264-w
work_keys_str_mv AT zhangyongchang diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT huangzhe diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT zengliang diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT zhangxiangyu diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT liyizhi diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT xuqinqin diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT yanghaiyan diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT lizasoanalyn diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT xuchunwei diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT liujun diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT wangwenxian diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT songzhengbo diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT ousaihongignatius diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements
AT yangnong diseaseprogressionpatternsandmolecularresistancemechanismstocrizotiniboflungadenocarcinomaharboringros1rearrangements

Ejemplares similares